Tags

Type your tag names separated by a space and hit enter

Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23.
Clin J Am Soc Nephrol. 2012 Apr; 7(4):624-31.CJ

Abstract

BACKGROUND AND OBJECTIVES

Fibroblast growth factor 23 is a phosphate- and vitamin D-regulating hormone. The objective of this study was to determine the effect of ergocalciferol administration on fibroblast growth factor 23 levels in healthy vitamin D-deficient subjects.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS

In this 12-week trial conducted in a clinical research center, 18- to 45-year-old subjects (n=90) with 25-hydroxyvitamin D levels ≤20 ng/ml (by chemiluminescent immunoassay) were randomized to weekly ergocalciferol treatment of 50,000 international units or placebo, while consuming a self-selected diet. Changes in fibroblast growth factor 23, 25-hydroxyvitamin D (by liquid chromatography/tandem mass spectroscopy), 1,25-dihydroxyvitamin D, parathyroid hormone, and serum phosphate were measured.

RESULTS

Mean 25-hydroxyvitamin D (P<0.0001), 1,25-dihydroxyvitamin D (P=0.01), and fibroblast growth factor 23 (P=0.003) increased in the treatment versus placebo group. In the treatment group, 25-hydroxyvitamin D increased from 18 ± 7 to 40 ± 12 ng/ml at week 4 (P<0.0001) and remained stable at 43 ± 12 ng/ml at week 12 (P<0.0001); 1,25-dihydroxyvitamin D increased from 42 ± 17 to 52 ± 18 pg/ml at week 4 (P<0.001) and then remained stable, and fibroblast growth factor 23 increased from 43 ± 17 to 60 ± 33 pg/ml at week 8 (P=0.001) and 74 ± 42 pg/ml at week 12 (P<0.0001). Urinary phosphate excretion increased within the treatment group, but parathyroid hormone and serum phosphate were unchanged.

CONCLUSIONS

Ergocalciferol administration increases circulating fibroblast growth factor 23. When measuring fibroblast growth factor 23, concurrent 25-hydroxyvitamin D measurements should be obtained, because vitamin D deficiency may lower circulating fibroblast growth factor 23 levels.

Authors+Show Affiliations

Endocrine Unit, Massachusetts General Hospital, Boston, USA. sburnett-bowie@partners.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22300739

Citation

Burnett-Bowie, Sherri-Ann M., et al. "Randomized Trial Assessing the Effects of Ergocalciferol Administration On Circulating FGF23." Clinical Journal of the American Society of Nephrology : CJASN, vol. 7, no. 4, 2012, pp. 624-31.
Burnett-Bowie SA, Leder BZ, Henao MP, et al. Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. Clin J Am Soc Nephrol. 2012;7(4):624-31.
Burnett-Bowie, S. A., Leder, B. Z., Henao, M. P., Baldwin, C. M., Hayden, D. L., & Finkelstein, J. S. (2012). Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. Clinical Journal of the American Society of Nephrology : CJASN, 7(4), 624-31. https://doi.org/10.2215/CJN.10030911
Burnett-Bowie SA, et al. Randomized Trial Assessing the Effects of Ergocalciferol Administration On Circulating FGF23. Clin J Am Soc Nephrol. 2012;7(4):624-31. PubMed PMID: 22300739.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. AU - Burnett-Bowie,Sherri-Ann M, AU - Leder,Benjamin Z, AU - Henao,Maria P, AU - Baldwin,Chantel M, AU - Hayden,Douglas L, AU - Finkelstein,Joel S, Y1 - 2012/02/02/ PY - 2012/2/4/entrez PY - 2012/2/4/pubmed PY - 2012/8/8/medline SP - 624 EP - 31 JF - Clinical journal of the American Society of Nephrology : CJASN JO - Clin J Am Soc Nephrol VL - 7 IS - 4 N2 - BACKGROUND AND OBJECTIVES: Fibroblast growth factor 23 is a phosphate- and vitamin D-regulating hormone. The objective of this study was to determine the effect of ergocalciferol administration on fibroblast growth factor 23 levels in healthy vitamin D-deficient subjects. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this 12-week trial conducted in a clinical research center, 18- to 45-year-old subjects (n=90) with 25-hydroxyvitamin D levels ≤20 ng/ml (by chemiluminescent immunoassay) were randomized to weekly ergocalciferol treatment of 50,000 international units or placebo, while consuming a self-selected diet. Changes in fibroblast growth factor 23, 25-hydroxyvitamin D (by liquid chromatography/tandem mass spectroscopy), 1,25-dihydroxyvitamin D, parathyroid hormone, and serum phosphate were measured. RESULTS: Mean 25-hydroxyvitamin D (P<0.0001), 1,25-dihydroxyvitamin D (P=0.01), and fibroblast growth factor 23 (P=0.003) increased in the treatment versus placebo group. In the treatment group, 25-hydroxyvitamin D increased from 18 ± 7 to 40 ± 12 ng/ml at week 4 (P<0.0001) and remained stable at 43 ± 12 ng/ml at week 12 (P<0.0001); 1,25-dihydroxyvitamin D increased from 42 ± 17 to 52 ± 18 pg/ml at week 4 (P<0.001) and then remained stable, and fibroblast growth factor 23 increased from 43 ± 17 to 60 ± 33 pg/ml at week 8 (P=0.001) and 74 ± 42 pg/ml at week 12 (P<0.0001). Urinary phosphate excretion increased within the treatment group, but parathyroid hormone and serum phosphate were unchanged. CONCLUSIONS: Ergocalciferol administration increases circulating fibroblast growth factor 23. When measuring fibroblast growth factor 23, concurrent 25-hydroxyvitamin D measurements should be obtained, because vitamin D deficiency may lower circulating fibroblast growth factor 23 levels. SN - 1555-905X UR - https://www.unboundmedicine.com/medline/citation/22300739/Randomized_trial_assessing_the_effects_of_ergocalciferol_administration_on_circulating_FGF23_ L2 - https://cjasn.asnjournals.org/cgi/pmidlookup?view=long&amp;pmid=22300739 DB - PRIME DP - Unbound Medicine ER -